Derik De Bruin
Stock Analyst at B of A Securities
(3.68)
# 759
Out of 5,152 analysts
223
Total ratings
65.77%
Success rate
16.15%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $410 → $350 | $315.59 | +10.90% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $38.50 | +55.84% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $118.11 | +39.70% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,261.21 | +10.21% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $202.00 | +8.91% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $49.59 | -45.55% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $96.57 | +13.91% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $21.64 | -39.93% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $46.44 | +8.70% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.13 | +114.42% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $103.32 | -37.09% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $9.13 | +75.25% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $518.84 | +27.21% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $178.50 | +31.65% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $181.32 | +15.82% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $244.35 | +45.28% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $15.91 | +63.42% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $275.92 | -1.78% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $203.98 | -10.78% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $9.92 | +111.69% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $13.03 | +145.59% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $128.24 | -22.02% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $75.75 | +13.53% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.12 | +317.34% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.84 | +253.26% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $110.60 | +135.08% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $6.84 | +1,654.39% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $122.23 | -1.82% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.04 | +341.18% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $618.92 | -62.03% | 3 | Nov 2, 2018 |
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $315.59
Upside: +10.90%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $38.50
Upside: +55.84%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $118.11
Upside: +39.70%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,261.21
Upside: +10.21%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $202.00
Upside: +8.91%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $49.59
Upside: -45.55%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $96.57
Upside: +13.91%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $21.64
Upside: -39.93%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $46.44
Upside: +8.70%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.13
Upside: +114.42%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $103.32
Upside: -37.09%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.13
Upside: +75.25%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $518.84
Upside: +27.21%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $178.50
Upside: +31.65%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $181.32
Upside: +15.82%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $244.35
Upside: +45.28%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $15.91
Upside: +63.42%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $275.92
Upside: -1.78%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $203.98
Upside: -10.78%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $9.92
Upside: +111.69%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $13.03
Upside: +145.59%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $128.24
Upside: -22.02%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $75.75
Upside: +13.53%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.12
Upside: +317.34%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.84
Upside: +253.26%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $110.60
Upside: +135.08%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $6.84
Upside: +1,654.39%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $122.23
Upside: -1.82%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.04
Upside: +341.18%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $618.92
Upside: -62.03%